Senti Biosciences Holdings, Inc. SNTI
At closeNov 6, 2026, 7:16 PM EST
After hours · Nov 6, 7:16 PM ET
- YTD
- -84.62%
- 1 year
- -91.16%
- Market cap
- 6.15M
- Revenue (ttm)
- 338.00K
- EPS (ttm)
- -1.72
- Shares out
- 4.59M
- Forward P/E
- -5.33
- YTD return
- -84.62%
- 1-year return
- -91.16%
- Volume
- 176.49K
- Avg volume
- 3.55M
- Open
- 0.155
- Previous close
- 0.1646
- Day's range
- 0.1574 – 0.1657
- 52-week range
- 0.16 – 2.39
- Beta
- 2.75
- Price target
- 12.00 (+7400.0%)
- Earnings date
- Aug 13, 2024
1Y -1.7900 (-91.79%)
Key statistics
- Enterprise value
- 29.64M
- PEG ratio
- 0.00
- Price / sales
- 54.30
- Price / book
- 0.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -57.74M
- Total cash
- 15.95M
- Total debt
- 35.74M
- Return on equity
- -111.07%
- Short % of float
- 1.80%
- 50-day average
- 3.26
- 200-day average
- 3.07
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -3.13.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -6.31 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -2.45 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -2.60 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -4.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 4, 2024 | Chardan Capital | main | Buy | Buy |
| Dec 2, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 15, 2023 | Chardan Capital | reit | Buy | Buy |
| May 11, 2023 | Chardan Capital | main | Buy | Buy |
| Mar 24, 2023 | Morgan Stanley | main | — | Equal-Weight |
| Mar 23, 2023 | Chardan Capital | main | — | Buy |
About Senti Biosciences Holdings, Inc.
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sentibio.com
News
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
12 Health Care Stocks Moving In Thursday's After-Market Session 
Senti Biosciences Files Prospectus Covering Resale Of Up To 25,555,024 Shares Of Common Stock Offered By The Selling Securityholders - 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on SNTI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DYNAMICS SPONSOR, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 7, 2022 | 0 |
| EPSTEIN DAVID R | Director | Stock Award(Grant) | Jun 7, 2022 | 123,252 |
| FAROKHZAD OMID | Director | Stock Award(Grant) | Jun 7, 2022 | 0 |
| KNOBELMAN DEBORAH A | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2024 | 131,000 |
| LU TIMOTHY K M.D., PH.D. | Chief Executive Officer | Stock Award(Grant) | Jan 31, 2024 | 1,922,280 |
| RAJANGAM KANYA | Officer | Stock Award(Grant) | Jan 31, 2024 | 101,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 9.65% | 442,615 | 1.77M | Sep 29, 2024 |
| 8vc Gp I, LLC | 5.53% | 253,755 | 1.02M | Sep 29, 2024 |
| ARK Investment Management, LLC | 3.85% | 176,666 | 706.66K | Sep 29, 2024 |
| Vanguard Group Inc | 2.12% | 97,467 | 389.87K | Sep 29, 2024 |
| Intel Corporation | 1.05% | 48,048 | 192.19K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.59% | 27,293 | 109.17K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Genomic Revolution ETF | 3.67% | 168,235 | 672.94K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.28% | 58,778 | 235.11K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.84% | 38,689 | 154.76K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 15,940 | 63.76K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 3,812 | 15.25K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 3,729 | 14.92K | Oct 30, 2024 |